Please assess the completion status of the following clinical trial:

Trial Title: Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 16 years~* Biopsy-proven diagnosis of classical Hodgkin Lymphoma (regardless of HRS cell CD20 expression) per the World Health Organization classification criteria24; lymphocyte predominant histology is excluded~* Untreated relapse of classical Hodgkin Lymphoma (with the exception of steroids) as follows:HL that relapsed \> 3 months after completion of first-line chemotherapy or combined modality therapy, and has not yet been treated with salvage chemotherapy, Stage I-II HL that relapsed \> 3 months after first-line chemotherapy, then relapsed after radiation therapy delivered with curative intent, and has not yet been treated with salvage chemotherapy~* Radiographically measurable disease (\> 1 focus of lymphoma measuring \> 1.5 cm)~* Baseline laboratories: ANC \> 1000/uL and platelets \> 75,000/uL, unless due to bone marrow involvement by lymphoma, Serum creatinine \< 2.0 mg/dL, Total bilirubin \< 2.0 mg/dL (excluding Gilbert's syndrome), unless due to lymphoma~* ECOG performance status 0, 1 or 2.~Exclusion Criteria:~* Active concurrent malignancy with the exception of superficial non-melanoma skin cancer and cervical carcinoma in situ.~* Primary induction failure, defined as failure to achieve CR with first-line chemotherapy or chemoradiation, disease progression during first-line chemotherapy or chemoradiation, or progression or biopsy-proven disease persistence within 8 weeks of first-line therapy completion~* Prior brentuximab vedotin or rituximab for lymphoma~* Grade \> 2 peripheral neuropathy~* HIV infection, active hepatitis B infection, or active hepatitis C infection

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin & Rituximab (Type: EXPERIMENTAL): Brentuximab vedotin:~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a \~ 1 year total course of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).